Indometacin Aspen Pharma (Indometacin)

Indometacin works by non‑selectively inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the conversion of arachidonic acid to prostaglandins. Lower prostaglandin levels diminish inflammation, pain, and fever.

The specific dose and dosing schedule for Indometacin Aspen Pharma are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Patients should follow the prescriber’s instructions precisely.

The safety of Indometacin in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indometacin is a potent non‑selective NSAID with strong anti‑inflammatory activity, often considered more effective for gout and certain rheumatic conditions than some other NSAIDs. However, its gastrointestinal and renal risk profile may be higher, so clinicians weigh benefits against potential adverse effects when selecting therapy.

Indometacin Aspen Pharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain stability.

The product is supplied as a rectal suppository. The suppository is inserted into the rectum, typically after bowel movements, following the prescriber’s instructions regarding timing and frequency.

Serious risks include gastrointestinal ulceration or bleeding, acute renal failure, severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for these events.

Indometacin should be avoided in individuals with known hypersensitivity to indometacin or other NSAIDs, active gastrointestinal ulceration, severe renal or hepatic impairment, and in patients with established cardiovascular disease unless specifically directed by a physician.